Research / Stocks / STIM STIM Nasdaq CIK 0001227636
Neuronetics, Inc. · Surgical & Medical Instruments & Apparatus
COVERAGE / STANDARD
Latest filing 8-K · Aug 17, 2026
Research state Latest filing analysis is current
Last SEC check Sep 13, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT Neuronetics, Inc.'s latest supported as-filed period reports revenue of $41.6M ; gross margin moved 446 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Debt relative to revenue RAW Current state valid · history insufficient
Method Level · gp.fundamentals.debt_to_revenue
Raw value 148.00% · OPTIONAL
Capex intensity RAW Current state valid · history insufficient
Method Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.00% · OPTIONAL
Operating cash generation RAW Current state valid · history insufficient
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -2.42% · OPTIONAL
Revenue growth RAW Current state valid · history insufficient
Method Yoy · gp.fundamentals.revenue
Raw value 9.08% · CORE
Inventory pressure RAW Current state valid · history insufficient
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 13.24% · OPTIONAL
Gross margin RAW Current state valid · history insufficient
Method Level · gp.fundamentals.gross_margin
Raw value 51.06% · CORE
Operating margin RAW Current state valid · history insufficient
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 30, 2026 General Corporate
Governance Evidence 4 evidence-backed dimensions Filing Amendments Repeated Auditor Changes None Detected Sbc Intensity Observed Insider Activity Observed [email protected] · 8 historical states · 50% confidenceInterpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
Inventory Pressure
STIM 13.2
Peer median 72.6
Peer percentile 5th 79 valid peers · 90% coverage · -1.9 robust σ Margin
STIM 51.1
Peer median 64.6
Peer percentile 24th 76 valid peers · 86% coverage · -0.8 robust σ R And D Intensity
STIM 3.2
Peer median 13.2
Peer percentile 15th 68 valid peers · 77% coverage · -0.7 robust σ Capex Intensity
STIM 1.0
Peer median 3.1
Peer percentile 26th 73 valid peers · 83% coverage · -0.6 robust σ Sbc Intensity
STIM 1.7
Peer median 5.9
Peer percentile 20th 81 valid peers · 92% coverage · -0.6 robust σ Cash Generation
STIM -2.4
Peer median -10.1
Peer percentile 54th 81 valid peers · 92% coverage · +0.2 robust σ Open group breadth → Divergence is context, not positive or negative. INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 1
Sales 0
Distinct buyers 1
Repeat buyer NO Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0001104659-26-094078 11 governed changes · top 7 shown
01
HIGH IMPORTANCE Cash 100TH HISTORICAL PCTL · N=2
Cash & equivalents increased 75.0% Cash & equivalents changed +75.0% from the comparable as-filed period.
Why this ranks here · [email protected] $11.0M → $19.2M Comparable → current
02
MEDIUM IMPORTANCE Debt 75TH HISTORICAL PCTL · N=4
Debt increased 10.8% Debt changed +10.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Why this ranks here · [email protected] $55.5M → $61.5M Comparable → current
03
HIGH IMPORTANCE Margin 67TH HISTORICAL PCTL · N=3
Gross margin moved 446 bp higher Gross margin changed +446 basis points from the comparable as-filed period.
Why this ranks here · [email protected] 46.60% → 51.06% Comparable → current
04
MEDIUM IMPORTANCE Margin 67TH HISTORICAL PCTL · N=3
Gross profit increased 19.5% Gross profit changed +19.5% from the comparable as-filed period.
As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 1.00% +75.5% ↑ Capital expenditure $417,000 +111.7% ↑ Cash & equivalents $19.2M +0.0% ↑ Debt $61.5M +0.4% ↑ Free-cash-flow proxy -$1.4M +85.2% ↑ Gross margin 51.06% +0.0% ↑ Interest expense $2.1M -6.2% ↓ Inventory $5.5M +16.7% ↑
ACTIVE TRACE Revenue STIM · as filed with the SEC · reported-date aware
Capex / revenue Q2 / 2026-06-30 1.00% +75.5% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q2 / 2026-06-30 $417,000 +111.7% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q2 / 2026-06-30 $19.2M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Debt Q2 / 2026-06-30 $61.5M +0.4% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q2 / 2026-06-30 -$1.4M +85.2% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q2 / 2026-06-30 51.06% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest expense Q2 / 2026-06-30 $2.1M -6.2% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q2 / 2026-06-30 $5.5M +16.7% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q2 / 2026-06-30 -$3.4M +68.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q2 / 2026-06-30 -$1.0M +89.3% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q2 / 2026-06-30 -3.61% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Research & development Q2 / 2026-06-30 $1.3M -2.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
8-K Aug 17, 2026 Period Aug 11, 2026 0001193125-26-354051SEC ↗ 4 Aug 17, 2026 Period Aug 13, 2026 0000921895-26-002204SEC ↗ 10-Q Aug 11, 2026 Period Jun 30, 2026 0001104659-26-094078SEC ↗ 8-K Aug 11, 2026 Period Aug 11, 2026 0001193125-26-343474SEC ↗ 4 Jul 23, 2026 Period Jul 23, 2026 0001982278-26-000006SEC ↗ 8-K Jul 20, 2026 Period Jul 9, 2026 0001193125-26-308921SEC ↗ 4 Jul 15, 2026 Period Jul 14, 2026 0000921895-26-001811SEC ↗ Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗